<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03034200</url>
  </required_header>
  <id_info>
    <org_study_id>CASE2716</org_study_id>
    <nct_id>NCT03034200</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of ONC201 in Neuroendocrine Tumors</brief_title>
  <official_title>Phase 2 Study of ONC201 in Neuroendocrine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter Anderson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn if a new drug, ONC201 can make tumors become smaller or&#xD;
      go away completely. Investigators also want to learn if ONC201 can prevent new deposits of&#xD;
      cancer from appearing in new places in participants (metastases). A phase 2 study of ONC201&#xD;
      in PC-PG (pheochromocytoma-paraganglioma) and other neuroendocrine tumors will determine&#xD;
      whether inhibition of DRD2 (a member of the dopamine receptor family) is safe in&#xD;
      unresectable, recurrent, locally advanced, refractory, or metastatic neuroendocrine cancers&#xD;
      including PC-PG, desmoplastic small round cell tumor (DSRCT), Ewing sarcoma (PNET) or any&#xD;
      other neuroendicrine tumor with a catecholamine or dopamine biomarker or autocrine or&#xD;
      paracrine dependence on dopamine including cholangiocarcinoma and adrenal cortical carcinoma.&#xD;
&#xD;
      ONC201 is an investigational (experimental) agent and has a favorable safety profile in phase&#xD;
      1 and early phase 2 clinical trials in advanced cancers. This study design has been chosen to&#xD;
      see whether ONC201 is associated with reduction of anti-hypertension medications, safety and&#xD;
      significant efficacy against neuroendocrine tumors, especially PC-PG.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective To demonstrate objective responses using MRI or CT, and/or PET-CT imaging.&#xD;
      The same CT or MRI imaging to assess disease burden at study entry will be compared at week 6&#xD;
      and 3 months. Patients without progression at 3 months will continue treatment and have&#xD;
      imaging at 6, 9 and 12 months after study entry. Metabolic response and/or biomarkers will be&#xD;
      compared with study entry PET-CT and scans at 6 weeks, 3 months and 12 months.&#xD;
&#xD;
      Secondary Objectives Progression - free Survival: This will be calculated according to&#xD;
      Response Evaluation Criteria In Solid Tumors (RECIST) or development of new disease&#xD;
&#xD;
      Overall survival: Overall survival will be determined by email or telephone contact.&#xD;
&#xD;
      Study Design: Phase 2 open-label fixed dose study Metastatic neuroendocrine tumors including&#xD;
      PC-PG are rare diseases.&#xD;
&#xD;
      The current recommended phase II dose of 625 mg orally on 2 consecutive days every week will&#xD;
      be used. The same imaging at study entry will be used at subsequent time points (CT or MRI&#xD;
      for week 6 and 3, 6, 9, and 12 months) Imaging modality choice will be influenced by the&#xD;
      quality of prior scans of the subject and will be ordered so clinical comparison is possible.&#xD;
&#xD;
      Because of travel and lodging considerations associated with the COVID-19 pandemic, some&#xD;
      information by the study team/PI may be obtained using virtual visits and 2nd read of scans&#xD;
      sent to Cleveland Clinic&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2, 2017</start_date>
  <completion_date type="Actual">November 30, 2022</completion_date>
  <primary_completion_date type="Actual">November 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response according to RECIST Criteria</measure>
    <time_frame>Up to 1 Year</time_frame>
    <description>Complete Response (CR) Disappearance or fibrosis of all target lesions. Any pathologic lymph nodes must have reduction in short axis to &lt;10mm and standardized uptake value (SUV) is &lt;4.&#xD;
Partial Response (PR) At least 30% decrease in sum of longest diameters of target lesions (compared to initial on study baseline) and any decrease in SUV in Fludeoxyglucose 18F (18FDG) imaging Stable disease (SD) 0-29% decrease in sum of longest diameters of target lesions (compared to initial on study baseline) or 0-19% increase in sum of longest diameters of target lesions (compared to initial on study baseline). SUV may increase or decrease Progressive disease 20% or more increase of sum of longest diameters of target lesions (compared to initial on study baseline). The sum must also be at an increase of at least 5mm or one or more new lesions that are considered metastatic disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average duration of lack of progression: Clinical response</measure>
    <time_frame>Up to 1 Year</time_frame>
    <description>Average time from beginning of treatment to progression, death, or one year, whichever comes first. An underlying clinical benefit rate of 25% would indicate that ONC201 has a therapeutic effect, whereas an underlying rate &lt;5% would indicate a lack of activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 1 Year</time_frame>
    <description>time from beginning of treatment until death, or one year, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average change in anti-hypertensive medication</measure>
    <time_frame>from beginning of treatment to 3 months</time_frame>
    <description>to achieve this secondary endpoint of anti-hypertensive medication reduction in PC-PG subjects (N=12) data at 3 months will be required. An underlying clinical benefit rate of 25% would indicate that ONC201 has a therapeutic effect, whereas an underlying rate &lt;5% would indicate a lack of activity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Recurrent Neuroendocrine Tumor</condition>
  <condition>Metastatic Neuroendocrine Tumor</condition>
  <arm_group>
    <arm_group_label>ONC201 phase 2 d1d2 weekly cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>625 mg ONC201 by mouth daily for 2 consecutive days weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONC201</intervention_name>
    <description>625mg ONC201 will be given on two consecutive days each week</description>
    <arm_group_label>ONC201 phase 2 d1d2 weekly cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. &quot;Subjects must have a unresectable, recurrent, locally advanced, refractory, or&#xD;
             metastatic neuroendocrine tumor including pheochromocytoma-paraganglioma (PC-PG),&#xD;
             DSRCT, Ewing Sarcoma or PNET, or any neuroendocrine tumor with a catecholamine or&#xD;
             dopamine biomarker or autocrine or paracrine dependence on dopamine including&#xD;
             cholangiocarcinoma and adrenal cortical carcinoma (ACC).&#xD;
&#xD;
          2. There is no limit on number of prior therapies.&#xD;
&#xD;
          3. Age ≥14 years.&#xD;
&#xD;
          4. Subjects must have normal organ and marrow function as defined below. Studies should&#xD;
             be done within 3 weeks prior to enrollment&#xD;
&#xD;
               -  Hemoglobin ≥ 10.0 g/dl&#xD;
&#xD;
               -  Leukocytes ≥ 1500/mcL&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1,000/mcL&#xD;
&#xD;
               -  Platelet count ≥ 75000/mcL&#xD;
&#xD;
               -  Total bilirubin within 1.5 x normal institutional limits&#xD;
&#xD;
               -  AST (SGOT) ≤ 5 X institutional upper limit of normal&#xD;
&#xD;
               -  ALT (SGPT) ≤ 5 X institutional upper limit of normal&#xD;
&#xD;
               -  Serum Creatinine &lt;3.0mg/dL&#xD;
&#xD;
                    -  5 1 lesion detectable on CT, MRI, 18FDG PET-CT&#xD;
&#xD;
        6 Subjects must have the ability to understand and the willingness to sign a written&#xD;
        informed consent document.&#xD;
&#xD;
        7: Karnofsky or if &lt;16 years old Lansky Play Performance status ≥ 60%&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter M Anderson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Pediatric and Taussig Cancer Institute, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, Dolloff NG, Messaris E, Scata KA, Wang W, Zhou JY, Wu GS, El-Deiry WS. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med. 2013 Feb 6;5(171):171ra17. doi: 10.1126/scitranslmed.3004828.</citation>
    <PMID>23390247</PMID>
  </reference>
  <reference>
    <citation>Allen JE, Krigsfeld G, Patel L, Mayes PA, Dicker DT, Wu GS, El-Deiry WS. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway. Mol Cancer. 2015 May 1;14:99. doi: 10.1186/s12943-015-0346-9.</citation>
    <PMID>25927855</PMID>
  </reference>
  <reference>
    <citation>Allen JE, Prabhu VV, Talekar M, van den Heuvel AP, Lim B, Dicker DT, Fritz JL, Beck A, El-Deiry WS. Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10. Cancer Res. 2015 Apr 15;75(8):1668-74. doi: 10.1158/0008-5472.CAN-14-2356. Epub 2015 Feb 13.</citation>
    <PMID>25681273</PMID>
  </reference>
  <reference>
    <citation>Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS. Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget. 2016 Nov 8;7(45):74380-74392. doi: 10.18632/oncotarget.11814. Erratum In: Oncotarget. 2021 Oct 12;12(21):2231.</citation>
    <PMID>27602582</PMID>
  </reference>
  <reference>
    <citation>Hayes-Jordan AA, Ma X, Menegaz BA, Lamhamedi-Cherradi SE, Kingsley CV, Benson JA, Camacho PE, Ludwig JA, Lockworth CR, Garcia GE, Craig SL. Efficacy of ONC201 in Desmoplastic Small Round Cell Tumor. Neoplasia. 2018 May;20(5):524-532. doi: 10.1016/j.neo.2018.02.006. Epub 2018 Apr 5.</citation>
    <PMID>29626752</PMID>
  </reference>
  <reference>
    <citation>Prabhu VV, Lulla AR, Madhukar NS, Ralff MD, Zhao D, Kline CLB, Van den Heuvel APJ, Lev A, Garnett MJ, McDermott U, Benes CH, Batchelor TT, Chi AS, Elemento O, Allen JE, El-Deiry WS. Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors. PLoS One. 2017 Aug 2;12(8):e0180541. doi: 10.1371/journal.pone.0180541. eCollection 2017.</citation>
    <PMID>28767654</PMID>
  </reference>
  <reference>
    <citation>Anderson PM, Hanna R. Defining Moments: Making Time for Virtual Visits and Catalyzing Better Cancer Care. Health Commun. 2020 May;35(6):787-791. doi: 10.1080/10410236.2019.1587695. Epub 2019 Mar 24.</citation>
    <PMID>30907145</PMID>
  </reference>
  <results_reference>
    <citation>Anderson PM, Trucco MM, Tarapore RS, Zahler S, Thomas S, Gortz J, Mian O, Stoignew M, Prabhu V, Morrow S, Allen JE. Phase II Study of ONC201 in Neuroendocrine Tumors including Pheochromocytoma-Paraganglioma and Desmoplastic Small Round Cell Tumor. Clin Cancer Res. 2022 May 2;28(9):1773-1782. doi: 10.1158/1078-0432.CCR-21-4030.</citation>
    <PMID>35022321</PMID>
  </results_reference>
  <verification_date>April 2022</verification_date>
  <study_first_submitted>January 25, 2017</study_first_submitted>
  <study_first_submitted_qc>January 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2017</study_first_posted>
  <last_update_submitted>December 1, 2022</last_update_submitted>
  <last_update_submitted_qc>December 1, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Case Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Peter Anderson</investigator_full_name>
    <investigator_title>Site Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pheochromocytoma-paraganglioma</keyword>
  <keyword>ONC201</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>TIC10 compound</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03034200
org study id: CASE2716
nct id: NCT03034200
lead sponsor: 
has dmc: Yes
is fda regulated drug: Yes
is fda regulated device: No
The purpose of this study is to learn if a new drug, ONC201 can make tumors become smaller or
      go away completely. Investigators also want to learn if ONC201 can prevent new deposits of
      cancer from appearing in new places in participants (metastases). A phase 2 study of ONC201
      in PC-PG (pheochromocytoma-paraganglioma) and other neuroendocrine tumors will determine
      whether inhibition of DRD2 (a member of the dopamine receptor family) is safe in
      unresectable, recurrent, locally advanced, refractory, or metastatic neuroendocrine cancers
      including PC-PG, desmoplastic small round cell tumor (DSRCT), Ewing sarcoma (PNET) or any
      other neuroendicrine tumor with a catecholamine or dopamine biomarker or autocrine or
      paracrine dependence on dopamine including cholangiocarcinoma and adrenal cortical carcinoma.

      ONC201 is an investigational (experimental) agent and has a favorable safety profile in phase
      1 and early phase 2 clinical trials in advanced cancers. This study design has been chosen to
      see whether ONC201 is associated with reduction of anti-hypertension medications, safety and
      significant efficacy against neuroendocrine tumors, especially PC-PG.
Primary Objective To demonstrate objective responses using MRI or CT, and/or PET-CT imaging.
      The same CT or MRI imaging to assess disease burden at study entry will be compared at week 6
      and 3 months. Patients without progression at 3 months will continue treatment and have
      imaging at 6, 9 and 12 months after study entry. Metabolic response and/or biomarkers will be
      compared with study entry PET-CT and scans at 6 weeks, 3 months and 12 months.

      Secondary Objectives Progression - free Survival: This will be calculated according to
      Response Evaluation Criteria In Solid Tumors (RECIST) or development of new disease

      Overall survival: Overall survival will be determined by email or telephone contact.

      Study Design: Phase 2 open-label fixed dose study Metastatic neuroendocrine tumors including
      PC-PG are rare diseases.

      The current recommended phase II dose of 625 mg orally on 2 consecutive days every week will
      be used. The same imaging at study entry will be used at subsequent time points (CT or MRI
      for week 6 and 3, 6, 9, and 12 months) Imaging modality choice will be influenced by the
      quality of prior scans of the subject and will be ordered so clinical comparison is possible.

      Because of travel and lodging considerations associated with the COVID-19 pandemic, some
      information by the study team/PI may be obtained using virtual visits and 2nd read of scans
      sent to Cleveland Clinic
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Tumor response according to RECIST Criteria
time frame: Up to 1 Year
description: Complete Response (CR) Disappearance or fibrosis of all target lesions. Any pathologic lymph nodes must have reduction in short axis to <10mm and standardized uptake value (SUV) is <4.
Partial Response (PR) At least 30% decrease in sum of longest diameters of target lesions (compared to initial on study baseline) and any decrease in SUV in Fludeoxyglucose 18F (18FDG) imaging Stable disease (SD) 0-29% decrease in sum of longest diameters of target lesions (compared to initial on study baseline) or 0-19% increase in sum of longest diameters of target lesions (compared to initial on study baseline). SUV may increase or decrease Progressive disease 20% or more increase of sum of longest diameters of target lesions (compared to initial on study baseline). The sum must also be at an increase of at least 5mm or one or more new lesions that are considered metastatic disease
measure: Average duration of lack of progression: Clinical response
time frame: Up to 1 Year
description: Average time from beginning of treatment to progression, death, or one year, whichever comes first. An underlying clinical benefit rate of 25% would indicate that ONC201 has a therapeutic effect, whereas an underlying rate <5% would indicate a lack of activity
measure: Overall survival
time frame: Up to 1 Year
description: time from beginning of treatment until death, or one year, whichever comes first.
measure: Average change in anti-hypertensive medication
time frame: from beginning of treatment to 3 months
description: to achieve this secondary endpoint of anti-hypertensive medication reduction in PC-PG subjects (N=12) data at 3 months will be required. An underlying clinical benefit rate of 25% would indicate that ONC201 has a therapeutic effect, whereas an underlying rate <5% would indicate a lack of activity
arm group label: ONC201 phase 2 d1d2 weekly cohort
arm group type: Experimental
description: 625 mg ONC201 by mouth daily for 2 consecutive days weekly
intervention type: Drug
intervention name: ONC201
description: 625mg ONC201 will be given on two consecutive days each week
arm group label: ONC201 phase 2 d1d2 weekly cohort
criteria: 
gender: All
minimum age: 14 Years
maximum age: N/A
healthy volunteers: No
last name: Peter M Anderson, MD, PhD
role: Principal Investigator
affiliation: Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
facility: 
country: United States
citation: Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, Dolloff NG, Messaris E, Scata KA, Wang W, Zhou JY, Wu GS, El-Deiry WS. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med. 2013 Feb 6;5(171):171ra17. doi: 10.1126/scitranslmed.3004828.
PMID: 23390247
citation: Allen JE, Krigsfeld G, Patel L, Mayes PA, Dicker DT, Wu GS, El-Deiry WS. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway. Mol Cancer. 2015 May 1;14:99. doi: 10.1186/s12943-015-0346-9.
PMID: 25927855
citation: Allen JE, Prabhu VV, Talekar M, van den Heuvel AP, Lim B, Dicker DT, Fritz JL, Beck A, El-Deiry WS. Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10. Cancer Res. 2015 Apr 15;75(8):1668-74. doi: 10.1158/0008-5472.CAN-14-2356. Epub 2015 Feb 13.
PMID: 25681273
citation: Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS. Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget. 2016 Nov 8;7(45):74380-74392. doi: 10.18632/oncotarget.11814. Erratum In: Oncotarget. 2021 Oct 12;12(21):2231.
PMID: 27602582
citation: Hayes-Jordan AA, Ma X, Menegaz BA, Lamhamedi-Cherradi SE, Kingsley CV, Benson JA, Camacho PE, Ludwig JA, Lockworth CR, Garcia GE, Craig SL. Efficacy of ONC201 in Desmoplastic Small Round Cell Tumor. Neoplasia. 2018 May;20(5):524-532. doi: 10.1016/j.neo.2018.02.006. Epub 2018 Apr 5.
PMID: 29626752
citation: Prabhu VV, Lulla AR, Madhukar NS, Ralff MD, Zhao D, Kline CLB, Van den Heuvel APJ, Lev A, Garnett MJ, McDermott U, Benes CH, Batchelor TT, Chi AS, Elemento O, Allen JE, El-Deiry WS. Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors. PLoS One. 2017 Aug 2;12(8):e0180541. doi: 10.1371/journal.pone.0180541. eCollection 2017.
PMID: 28767654
citation: Anderson PM, Hanna R. Defining Moments: Making Time for Virtual Visits and Catalyzing Better Cancer Care. Health Commun. 2020 May;35(6):787-791. doi: 10.1080/10410236.2019.1587695. Epub 2019 Mar 24.
PMID: 30907145
citation: Anderson PM, Trucco MM, Tarapore RS, Zahler S, Thomas S, Gortz J, Mian O, Stoignew M, Prabhu V, Morrow S, Allen JE. Phase II Study of ONC201 in Neuroendocrine Tumors including Pheochromocytoma-Paraganglioma and Desmoplastic Small Round Cell Tumor. Clin Cancer Res. 2022 May 2;28(9):1773-1782. doi: 10.1158/1078-0432.CCR-21-4030.
PMID: 35022321
responsible party type: Sponsor-Investigator
investigator affiliation: Case Comprehensive Cancer Center
investigator full name: Peter Anderson
investigator title: Site Principal Investigator
mesh term: Neoplasms
mesh term: Neuroendocrine Tumors
mesh term: TIC10 compound
sharing ipd: No